| A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer |
Ongoing |
Lasertinib |
2 |
61186372NSC2012 |
King Khalid University Hospital (Riyadh), King Abdulaziz Medical City NG (Riyadh) |
| A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atumelnant in Adult Participants with Classic Congenital Adrenal Hyperplasia |
Ongoing |
Atumelnant |
3 |
CRN04894-12 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Real-World, International, MultICentre, Non-Interventional, Prospective CoHORt to Assess the Clinical and Patient-Reported Outcomes in Adults with MOderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Treated with Breztri/Trixeo (Budesonide /Glycopyrronium / Formoterol) in Routine Care Settings |
Ongoing |
Budesonide/ Glucopyrronim/ Formoteral |
4 |
D5980R0012 |
King Fahad Medical City (Riyadh),Abha Private Hospital (Aseer) |
| A Phase 3b, Multicenter, Randomized, Open-Label Study of Risankizumab Compared to Vedolizumab for the Treatment of Adult Subjects With Moderate to Severe Ulcerative Colitis Who are Naïve to Targeted Therapies |
Ongoing |
Risankizumab |
3b |
M25-540 |
King Khalid University Hospital (Riyadh), King Fahad Specialist Hospital (Dammam), King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Medical City, National Guard Health Affairs (Riyadh) |
| A Multicenter, Single Arm, Open Label Biopsy Study to Evaluate Structural and Functional Changes in Kidneys of Adult Patients with Iga Nephropathy Receiving Iptacopan on Top of Supportive Care |
Ongoing |
Iptacopan (LNP023) |
2a |
CLNP023A2201 |
King Faisal Specialist Hospital and Research Center (Riyadh). |
| DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer (DESTINY BTC01 - D781PC00001) |
Ongoing |
Trastuzumab-Deruxtecan,Rilvegostomig &Durvalumab |
3 |
D781PC00001 |
King Faisal Specialist Hospital and Research Center (Riyadh). |
| A Retrospective Phase IV Study: Use of the clinical decision support tool (CDST) in predicting probability of response to vedolizumab in Middle Eastern Crohn’s Disease patients: the ME-VOICE study (Middle East Vedolizumab Outcomes probability In CDST Evaluation |
Ongoing |
Vedolizumab |
4 |
CCR-2024-2 |
King Khalid University Hospital (Riyadh),King AbdulAziz University Hospital (Jeddah) |
| A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel- group study with an open-label period and long-term extension to assess the efficacy and safety of rilzabrutinib in participants with warm autoimmune hemolytic anemia (wAIHA) |
Ongoing |
Rilzabrutinib |
3 |
EFC17360 |
King Faisal Specialist Hospital and Research Center (Riyadh). |
| A Global Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of mRNA-3705 in Participants with Isolated Methylmalonic Acidemia Due to Methylmalonyl-CoA Mutase Deficiency |
Ongoing |
MRNA 3705 |
2 |
mRNA-3705-P101 |
King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Medical City (Riyadh) , King Abdullah Specialist Children's Hospital (Riyadh) |
| Multi-center, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of self-administered subcutaneous selatogrel for prevention of all-cause death and treatment of acute myocardial infarction in subjects with a recent history of acute myocardial infarction |
Ongoing |
(ACT-246475) is a 2-phenyl-pyrimidine derivative selatogrel |
3 |
ID-076A301 / SOS-AMI |
King Faisal Specialist Hospital and Research Center (Riyadh),King Saud University Medical City (Riyadh), King Fahad Specialist Hospital (Dammam),King Abdulaziz Medical City NG (Riyadh), King Abdulaziz Medical City NG (Jeddah) |
